Prostatype Genomics AB (publ) (PROGEN.ST)

SEK 1.85

(-1.86%)

Net Income Summary of Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)'s latest annual net income in 2023 was -41.43 Million SEK , down -42.45% from previous year.
Prostatype Genomics AB (publ)'s latest quarterly net income in 2024 Q2 was -9.83 Million SEK , down 0.0% from previous quarter.
Prostatype Genomics AB (publ) reported an annual net income of -29.08 Million SEK in 2022, down -86.1% from previous year.
Prostatype Genomics AB (publ) reported an annual net income of -15.62 Million SEK in 2021, up 10.22% from previous year.
Prostatype Genomics AB (publ) reported a quarterly net income of -9.83 Million SEK for 2024 Q1, up 16.46% from previous quarter.
Prostatype Genomics AB (publ) reported a quarterly net income of -7.81 Million SEK for 2023 Q1, up 4.28% from previous quarter.

Annual Net Income Chart of Prostatype Genomics AB (publ) (2023 - 2015)

Historical Annual Net Income of Prostatype Genomics AB (publ) (2023 - 2015)

Year	Net Income	Net Income Growth
2023	-41.43 Million SEK	-42.45%
2022	-29.08 Million SEK	-86.1%
2021	-15.62 Million SEK	10.22%
2020	-17.4 Million SEK	0.0%
2018	-8.54 Million SEK	8.29%
2017	-9.31 Million SEK	-96.31%
2016	-4.74 Million SEK	58.69%
2015	-11.49 Million SEK	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-9.83 Million SEK	0.0%
2024 Q1	-9.83 Million SEK	16.46%
2023 Q1	-7.81 Million SEK	4.28%
2023 FY	-41.43 Million SEK	-42.45%
2023 Q2	-10.08 Million SEK	-29.12%
2023 Q3	-11.77 Million SEK	-16.71%
2023 Q4	-11.77 Million SEK	0.0%
2022 FY	-29.08 Million SEK	-86.1%
2022 Q4	-8.15 Million SEK	-2.2%
2022 Q3	-7.98 Million SEK	-8.05%
2022 Q2	-7.38 Million SEK	-33.01%
2022 Q1	-5.55 Million SEK	3.44%
2021 Q1	-3.42 Million SEK	18.05%
2021 FY	-15.62 Million SEK	10.22%
2021 Q4	-5.75 Million SEK	-57.38%
2021 Q3	-3.65 Million SEK	-54.6%
2021 Q2	-2.36 Million SEK	30.91%
2020 FY	-17.4 Million SEK	0.0%
2020 Q4	-4.17 Million SEK	-12.36%
2020 Q3	-3.71 Million SEK	10.94%
2020 Q2	-4.17 Million SEK	-157.5%
2020 Q1	-1.62 Million SEK	12.9%
2019 Q4	-1.86 Million SEK	-47.46%
2019 Q3	-1.26 Million SEK	0.0%
2018 FY	-8.54 Million SEK	8.29%
2017 FY	-9.31 Million SEK	-96.31%
2016 FY	-4.74 Million SEK	58.69%
2015 FY	-11.49 Million SEK	0.0%

Peer Net Income Comparison of Prostatype Genomics AB (publ)

Name	Net Income	Net Income Difference
AroCell AB (publ)	-59.29 Million SEK	30.123%
Devyser Diagnostics AB (publ)	-53.6 Million SEK	22.696%
Immunovia AB (publ)	-309.43 Million SEK	86.61%
SenzaGen AB	-22.09 Million SEK	-87.514%
Spermosens AB	-12.2 Million SEK	-239.575%